Engineered AAV capsids for transduction of neurofibroma and peripheral nerve
Engineered AAV capsids with specific amino acid sequences improve transduction efficiency in neurofibroma and peripheral nerves, achieving enhanced biodistribution and reduced liver off-target effects, addressing the limitations of current AAV vectors in these tissues.
Patent Information
- Application Number
- PCT/US2026/026968
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-07
- Filing Date
- 2026-05-06
- Publication Date
- 2026-11-12
AI Technical Summary
Current AAV vectors are less effective for transduction of neurofibroma and peripheral nerves, particularly in the complex cellular environment of neurofibroma, which is a benign yet complex mixed-cell tumor, and there is a need for improved biodistribution and transduction strategies for gene therapy in neurofibroma and peripheral nerves.
Engineered AAV capsids with specific amino acid sequences, such as RPDHLPP (SEQ ID NO:3) and GATPSTQ (SEQ ID NO:4), enhance biodistribution and transduction to neurofibroma and peripheral nerves, particularly through systemic administration, using AAV9 capsid proteins with inserted peptides at specific positions.
The engineered AAV capsids demonstrate enhanced transduction efficiency in neurofibroma and peripheral nerves, with up to 6-fold increased biodistribution and transgene expression, while maintaining brain biodistribution and reducing liver off-target effects.
Smart Images

Figure IMGF000005_0001_TABLE 
Figure IMGF000011_0001_TABLE 
Figure IMGF000020_0001_TABLE
Abstract
Description
[0001] Atorney Docket No. 29539-0872WO1 / MGH 2025-338
[0002] ENGINEERED AAV CAPSIDS FOR TRANSDUCTION OF NEUROFIBROMA AND PERIPHERAL NERVE CLAIM OF PRIORITY
[0003] This application claims the benefit of U.S. Provisional Application Serial No.
[0004] 63 / 801,707, filed on May 7, 2025. The entire contents of the foregoing are incorporated herein by reference.
[0005] SEQUENCE LISTING
[0006] This application contains a Sequence Listing that has been submitted electronically as an XML file named “29539-0872WOl_SL_ST26.XML.” The XML file, created on May 6, 2026, is 54,249 in size. The material in the XML file is hereby incorporated by reference in its entirety.
[0007] FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
[0008] This invention was made with Government support under Grant Nos.
[0009] DC017117and EB032864 awarded by the National Institutes of Health. The Government has certain rights in the invention.
[0010] TECHNICAL FIELD
[0011] Described herein are AAV capsids with an enhanced ability to biodistribute to and transduce neurofibroma and peripheral nerve after systemic administration, and methods of use thereof for delivery to those tissues.
[0012] BACKGROUND
[0013] Adeno-associated virus (AAV) vectors are currently the lead in vivo gene therapy system owing to their relatively efficient transduction of differentiated or slowly dividing cell types in the brain, muscle, and liver(l). Currently, there are seven FDA- and European Medicines Agency-approved AAV-based medicines to treat genetic diseases(2-6). Several other gene therapy trials are underway using AAV vectors for gene delivery. However, AAV is less developed for peripheral nerve transduction. In recent years, the Kleopa group has tested AAV vectors for transduction of Schwann cells (SCs) in adult mice with some success(7). They found that AAV9 and AAVrhlO transduced SCs when transgene expression was controlledAtorney Docket No. 29539-0872WO1 / MGH 2025-338
[0014] with the P0 (MPZ) promoter and delivered via intrathecal or intravenous (i.v.) injection in adult mice(7, 8). Tanguy et al. observed that AAV9 and AAVrhlO could transduce SCs in neonatal mice via i.v. injection(9) and Homs et al. showed transduction of SCs by direct nerve injection of AAV8(10). We also observed transduction of sciatic nerve SCs in non-human primates (NHPs) after intrathecal injection of the engineered AAV-F capsid(ll).
[0015] Neurofibroma is a benign yet complex mixed-cell tumor, composed of neoplastic SCs, axonal processes, perineurial cells, fibroblasts, endothelial cells, and immune cells (mast cells and macrophages), with excessive extracellular matrix, which develop within peripheral nerve sheaths(12). Neurofibroma initiate due to loss of NF1 function in the SC lineage(13), followed by a cascade of interactions with other cell types in the surrounding tumor microenvironment. There is an urgent medical need to develop therapies that address the underlying genetic abnormalities in NF1 neurofibroma. AAV-based gene therapy to treat NF 1 is one potential strategy, although there has been little to no characterization of their biodistribution and transduction in preclinical models of NF1, which may differ from other models owing to the complex nature of the cellular environment of these tumors as mentioned above.
[0016] SUMMARY
[0017] Described herein are AAV capsids with an enhanced ability to biodistribute to and transduce neurofibroma and peripheral nerves after systemic administration.
[0018] Provided herein are engineered AAV capsid proteins comprising an amino acid sequence that comprises at least four, five, six, or all seven contiguous amino acids from a sequence shown in Table 2, e.g., the sequence GATPSTQ (SEQ ID NO:4) or RPDHLPP (SEQ ID NO:3) or LPTPQRL (SEQ ID NO:2).
[0019] In some embodiments, the AAV capsid protein comprises the sequence RPDHLPP (SEQ ID NO:3) and GATPSTQ (SEQ ID NO:4).
[0020] In some embodiments, the AAV capsid protein comprises the sequence GATPSTQ (SEQ ID NO:4).
[0021] In some embodiments, the AAV is AAV9.
[0022] In some embodiments, the AAV capsid protein comprises AAV9 VP1.
[0023] In some embodiments, the amino acid sequence is inserted in a position corresponding to amino acids 588 and 589 of SEQ ID NO:6.Atorney Docket No. 29539-0872WO1 / MGH 2025-338
[0024] Also provided herein are nucleic acids encoding the AAV capsid proteins. Additionally provided herein are AAV comprising the capsid protein described herein, and preferably not comprising a wild type VP1, VP2, or VP3 capsid protein.
[0025] In some embodiments, the AAV further comprises a transgene, preferably a therapeutic transgene.
[0026] Additionally provided herein are methods of delivering a transgene to a cell, the method comprising contacting the cell with an AAV as described herein.
[0027] In some embodiments, the cell is a schwann cell.
[0028] In some embodiments, the cell is in a living subject, e.g., a mammalian subject, e.g., a human or non -human veterinary subject.
[0029] In some embodiments, the cell is in the peripheral nervous system (PNS) of the subject.
[0030] In some embodiments, the subject has Neurofibromatosis type 1 (NF1) or NF2. In some embodiments, the transgene is selected from the group consisting of caspase- 1 (interleukin-P-converting enzyme; ICE), the pore-forming protein Gasdermin-D, apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), functional merlin (the protein product of the NF2 gene), the NF1 GRD domain, and CRISPR-associated protein 9 (CRISPR / Cas9) base editor with a guide RNA (gRNA) directing the base editor to correct point mutations in the NF2 gene.
[0031] In some embodiments, the subject has Charcot-Marie-Tooth. In some embodiments, the transgene is selected from the group consisting of peripheral myelin protein 22 (PMP22); gap junction protein beta 1 (GJB1); mitofusin 2 (MFN2); or myelin protein zero (MPZ).
[0032] In some embodiments, the cell is in the PNS of the subject, and the AAV is administered by parenteral delivery. In some embodiments, the parenteral delivery is via intravenous, intraarterial, subcutaneous, intraperitoneal, or intramuscular delivery.
[0033] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Methods and materials are described herein for use in the present invention; other, suitable methods and materials known in the art can also be used. The materials, methods, and examples are illustrative only and not intendedAtorney Docket No. 29539-0872WO1 / MGH 2025-338
[0034] to be limiting. All publications, patent applications, patents, sequences, database entries, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control.
[0035] Other features and advantages of the invention will be apparent from the following detailed description and figures, and from the claims.
[0036] DESCRIPTION OF DRAWINGS FIGs. la-e. NFlflox / flox / Flucfloxinduced tumor mouse model and characterization of neurofibroma, a. Overview of NF1 mouse model generation. Transgenic mice contain both NF1 floxed alleles and a floxed stop firefly luciferase (Flue) cassette. AAV-Cre injection into the sciatic nerve induces neurofibroma formation which can be monitored by Flue bioluminescence, b. left image: In vivo bioluminescence imaging of neurofibroma showing Flue activity detected on the left sciatic nerve indicating tumor formation, right graph: Increased Flue activity seen on the sciatic nerve bearing neurofibroma corresponds to the tumor growth post-injection with AAVl-CBA-Cre vector (n=9). Inset image: Compared to the contralateral naive nerve, “n” (NF+ / +), the sciatic nerve bearing neurofibroma, “N” (NF”), is markedly thickened and highly vascularized, c. Hematoxylin & Eosin staining. Sagittal section of the naive sciatic nerve (left image) and neurofibroma (right image). Sciatic nerve bearing neurofibroma demonstrated features of early neurofibroma such as hypercellularity and mast cells infiltration (arrows), d. Comparing the sagittal section of the naive sciatic nerve (left image), there are more Sox 10-positive cells in the neurofibroma within the hypercellular area (right image), e. At 14 weeks postimplantation, naive sciatic nerve has no to minimal Ki67-positive cells (left image), whereas the sciatic nerve with neurofibroma shows marked Ki67 signal indicating high mitotic activity at the tumor site (right image).
[0037] FIGs.2a-b. In vivo selection with an AAV peptide display library allows enrichment of variants recovered from the second round in the sciatic nerve of M'lllovllo'7Fluc11"' induced tumor model, a. In vivo library two-round selection scheme to isolate AAV capsid variants that transduce neurofibroma, b. Round two next generation sequencing (NGS) results of AAV peptide inserts isolated from the neurofibroma (tumor) and naive (no tumor) nerve. Each chart shows enrichment after second round of library selection, with darker shading representing higher readAttorney Docket No. 29539-0872WO1 / MGH 2025-338
[0038] frequency. The bottom region of each chart (“Others”) represents all of the other sequence variants. Shown are SEQ IDNOs:5-12, 1, 13, 3, 14-16, 2, 17, 18, 4, and 19- 34 in order of appearance; repeated sequences are not listed in the table below.
[0039] Sequence SEQ ID NO:
[0040] PTTRHIT 5 TQIALNW 6 GQNKAAS 7 PTASPPM 8 YRPDE* 9 PTLPPQP 10 YITTVYQ 11 LSGSPGH 12 STTLYSP 1 TTPDRIH 13 RPDHLPP 3 GTPLDHH 14 RTQGDPC 15 HPFVSLA 16 LPTPQRL 2 QCSGMTT 17 PRLVSNS 18 GATPSTQ 4 APYELQK 19 VADTPNW 20 RQPFTNN 21 LTTPTHR 22 PPLPQQP 23 AIYMYDD 24 SGFVSNS 25 AVLMQAA 26 SPFEYDD 27 AWFTNAI 28
[0041] LCSR* 29 PPTTPAG 30 HRRLPRP 31 PARYYVP 32 TINEDLH 33
[0042]
[0043] PRHPPTL 34
[0044] FIGs. 3a-e. AAV-SC3 displays similar biodistribution to liver and brain as AAV9, but increased transgene expression in sciatic nerve of neurofibromabearing mice. a. An AAV expression cassette was constructed with a rat PO promoter driving tdT cDNA expression. Nflflox / flox / Flucfloxmice had neurofibroma induced in both sciatic nerves with local AAVl-Cre injection. After neurofibroma formation,Atorney Docket No. 29539-0872WO1 / MGH 2025-338
[0045] mice were injected i.v. with three groups of capsids packaging the expression cassette. Six weeks post-injection both neurofibroma were harvested as well as brain and liver for molecular and histological analysis. ITR, inverted terminal repeat; WPRE, woodchuck hepatitis virus post-transcriptional regulatory element; pA, polyadenylation signal, b. Biodistribution of AAV genomes in brain and liver. ** p=0.008. c. RT-ddPCR quantitation of tdT mRNAin whole neurofibroma-bearing nerves from each group of mice. ns=not significant; ** p=0.008. d.
[0046] Immunofluorescence detection of tdT expression in neurofibroma of mice injected with AAV vectors. Specific labeling of anti-tdT immunostained cells of SC morphology were observed in the injected mice, most frequently in the AAV9 and AAV-SC3 injected groups. Scale bar=100 pm. DAPI; tdT immunofluorescence, e. AAV9 and AAV-SC3 can both transduce SCs in neurofibroma. Sections were immunostained for transgene expression (tdT) and SoxlO. Co-localized cells are shown in white and indicated by black arrows. For b. and c.: AAV9, n=5; AAV-F, n=5; AAV-CAP.NF, n=4 For d.: AAV-9, n=4; AAV-F, n=5; AAV-SC3, n=4.
[0047] FIGs. 4a-c. Identification of an AAV capsid variant with enhanced biodistribution to sciatic nerve after systemic injection, a. Schematic of experiment. Four capsids from the in vivo selection SC 1-4 as well as AAV9 were produced, each packaging a uniquely barcoded genome. The pooled capsids were injected systemically into C57B1 / 6 mice and two weeks later sciatic nerve and other tissues harvested and barcode read frequency determined using NGS of the amplified AAV genomes, b. Heat map of read frequency for each capsid variant normalized to AAV9 reads for each tissue, c. Graph of fold-change for each capsid across different tissues, ns, not significant; ***p<0.001.
[0048] FIGs. 5a-d. Side by side comparison of AAV9 and AAV-SC4 biodistribution to and transduction of sciatic nerve in C57BL / 6 mice after systemic administration, a. AAV9 or AAV-SC4 vectors packaging AAV-P0-tdTomato were injected systemically into male (n=3) and female (n=3) C57BL / 6 mice (total n=6 / vector group). Seven weeks later, sciatic nerves were harvested to quantitate AAV genomes and tdTomato expression, b. AAV genome quantitation in sciatic nerve. Each data point represents an individual mouse. The dotted line indicates qPCR values from control mice not treated with vector. **p=0.0027. c. DataAtorney Docket No. 29539-0872WO1 / MGH 2025-338
[0049] in b separated by mouse sex. d. RT-ddPCR quantitation of tdT mRNA in whole neurofibroma nerves from each group of mice.
[0050] FIGs. 6a-d. AAV-SC4 capsid packaging a self-complementary (sc) AAV-CAG-GFP genome transduces sciatic nerve after systemic injection, a. Overview of experiment. AAV-SC4 packaged a sc AAV-CAG-GFP expression cassette. mITR, mutated ITR. Tail vein injection of the vector into C57BL / 6 mice and 3 weeks later, liver and sciatic nerve were harvested for immunofluorescence analysis, b. Liver is highly transduced by AAV-SC4-scCAG-GFP. Scale bar= 200 pm. c. Representative nerve of control, no vector mouse, and AAV-SC4 injected mouse. Scale bar= 100 pm d. High magnification image of a nerve from a AAV-SC4 injected mouse. Scale bar= 20 pm. In c and d, SOX10 immunostaining and GFP immunostaining can be seen. Arrows point to co-localized GFP / SOX10 immunostaining which indicates transduced Schwann cells.
[0051] FIGs. 7a-g. AAV9 and AAV-SC3 biodistribution and transduction of sciatic nerve and liver in systemically injected C57BL / 6 mice. a. AAV expression cassette a rat P0 promoter driving tdT cDNA expression was packaged into either AAV9 of AAV-SC3 capsids. Adult mice were injected i.v. with each capsid (n=5 / capsid). Seven weeks post-injection both sciatic nerves were harvested as well as liver for molecular and histological analysis, b. Biodistribution of AAV genomes in sciatic nerve and liver. Ns, not significant; p=0.01 by one way ANOVA. c. Ratio of sciatic nerve / liver biodistribution for each capsid. d. RT-ddPCR quantitation of tdT mRNA in sciatic nerve for each vector group, e. RT-ddPCR quantitation of tdT mRNA in liver for each vector group, f. Immunofluorescence detection of tdT expression in liver of mice injected with AAV vectors. Specific labeling of anti -tdT immunostained cells is shown in representative mice. Scale bar=100 pm. g. Immunofluorescence detection of tdT expression in sciatic nerve of mice injected with AAV vectors.
[0052] Specific labeling of anti-tdT immunostained cells is shown in representative mice. DAPI; tdT immunofluorescence; SoxlO. Vector transduced Sox 10-positive cells are shown in white and indicated by black arrows. Scale bars=100 pm.
[0053] FIGs. 8a-c. The SC4 peptide binds to human laminins 1 and 2.
[0054] Nitrocellulose membranes were spotted with recombinant human laminin 1 (Hl), human laminin 2 (H2), and mouse laminin 1 (Ml). Next blots were probed with biotinylated SC4 peptide, GATPSTQ (a.), b. biotinylated STQNASLLSLTV (positiveAtorney Docket No. 29539-0872WO1 / MGH 2025-338
[0055] control), or c. biotinylated scrambled SC4 peptide (negative control) Specific binding was detected via Streptavidin-horseradish peroxidase chemiluminescence (black spots).
[0056] DETAILED DESCRIPTION
[0057] While AAVs have been evaluated for transduction ability in peripheral nerves in mice(7), the present study tested different AAV vectors injected systemically for gene delivery to peripheral nerves and neurofibromas in an in vivo model of NF1. As part of this study, a novel nerve-associated NF 1 mouse neurofibroma model was developed that produced focal neurofibroma in the sciatic nerve after injection of AAVl-Cre into young adult Nflflox / flox / Flucfloxmice, so that the presence and size of tumors could be monitored by in vivo bioluminescence imaging. Using a somewhat related model, Dodd et al. (29) injected adenovirus-Cre into the sciatic nerve of Nrflflox / flox mice. In the present models, bioluminescent tumors appeared within 3-8 weeks, which were deemed to resemble early neurofibroma in NF1 patients using H&E neuropathology and IHC for the SC marker, SoxlO and proliferation marker, Ki67(30). This neurofibroma model was used together with an AAV9 peptide display library to identify a novel capsid variant, AAV-SC3, that mediates transduction of neurofibroma in mice after systemic delivery. Compared to the parental capsid, AAV9, enhanced transduction of neurofibroma (2.1 -fold) was observed after systemic injection in mice. The P0 promoter was used based on earlier work as it drives selective expression in SCs. While this did not achieve statistical significance (p=0.111 ) at the group sizes tested (n=4-5 mice), it did provide promising proof of concept data that AAV capsid engineering and in vivo selections can lead to transduction of neurofibroma. The AAV-SC3 (peptide RPDHLPP, SEQ ID NO:3) was chosen as it was represented in the top sequencing reads in two mouse neurofibromas (Fig. 2). A screen of four chosen candidate capsids from round two of the selection (AAV-SC1-4; Table 2) was also performed. This selection included AAV-SC3 as well as AAV9 for benchmarking the new capsids. The goal of the screen was to identify capsids that distribute to the normal sciatic nerve after systemic injection in healthy mice. Through this selection a new capsid, AAV-SC4, was identified that mediated 6-fold enhanced biodistribution to sciatic nerve compared to AAV9. Interestingly, no significant increase in P0 promoter-driven transgene expression of AAV-SC4 over AAV9 was observed, which made us question whether the capsid was functional atAtorney Docket No. 29539-0872WO1 / MGH 2025-338
[0058] transduction. To test this, a self-complementary AAV-CBA-GFP expression cassette was packaged into AAV-SC4. The broadly active CB A promoter was chosen to assess a wider array of cell types in the nerve, as the P0 promoter has higher activity in myelinating SCs (MSCs) vs non-myelinating SCs (NMCs)(31). Using this promoter, AAV-SC4 mediated transduction of cells throughout the sciatic nerve, confirming the capsid’s transduction capability. Confocal microscopy using staining for GFP and SOXIO was performed to understand whether MSCs and / or NMSCs were transduced by AAV-SC4. There was colocalization of some of the GFP positive cells with SOX10-positive cells, which indicates that AAV-SC4 can indeed transduce SCs.
[0059] This result also indicated that the P0 promoter (at least the version utilized here) may not always be the best option for transgene expression in SCs, particularly those with lower activity of this promoter. Another explanation for the lack of apparent P0 promoter activity with SC4 in contrast to SC3 and AAV9 could be due to differences of this capsid recruiting transcriptional machinery to this promoter in the AAV genome as described (32-34). Since the CBA promoter does seem to be active in SCs (Fig. 6), detargeting expression from neurons may be achieved using miRNA-based expression detargeting (e.g., using miR9, miR124) as has been done to increase transduction selectivity for microglia (35).
[0060] AAV-SC4 contains a known laminin binding motif, STQ. Schwann cells and neurofibroma both secrete laminin, localized primarily to the basement membrane (36). One study identified STQ-motif containing peptides that selectively bound denatured laminin using bacteriophage peptide display (27). The identified STQ peptide was found to reduce tumor cell migration, angiogenesis, and metastasi s(27) in mice. In another independent study, phage display identified an STQ-containing peptide that bound to the vesicular stomatitis virus glycoprotein (VSV-G) on lentiviruses and this allowed increased lentivirus transduction of HT1080 cells(37). While the in vivo selection strategy used herein did not intentionally target laminin, the identification of an amino acid motif with a known ligand for peripheral nerve / neurofibroma may be useful for further improving AAV and other delivery modalities (e.g. extracellular vesicles, lipid nanoparticles, etc.). Other routes of administration of AAV-SC4 can also be used, e.g., intrathecal or direct intra-nerve injection. AAV-SC4 can also be used for transduction of neurofibroma, as the AAV-Atorney Docket No. 29539-0872WO1 / MGH 2025-338
[0061] SC4 peptide was detected in both neurofibroma and normal nerve in round two of selection (Fig. 2b).
[0062] Several studies have tested existing AAV serotypes for transduction of SCs after various routes of injection as described above. A recent study used an AAV peptide display library to identify AAV capsids that could transduce primary human SCs in culture (39). These peptides (Pep2hSCl (RKRGDSWSE, SEQ ID NO:59) and Pep2hSC2 (RRKDVDFDK, SEQ ID NO: 60)) were inserted within the AAV2 capsid. The authors showed that these capsids could transduce human and rodent SCs, human plexiform neurofibroma cells as well as human nerve segments upon direct injection ex vivo. Interestingly, they observed better transduction efficiency in “healthy” SCs than NF 1 patient-derived SCs, which may be due to the selection method based on healthy patient SCs. Finally, they achieved transduction of SCs in a nerve crush model in mice after direct intra-nerve injection. Both the AAV2 -based Pep2hSC capsids as well as the AAV-SC3 and AAV-SC4 capsids described herein may serve roles in NF1 / SC research. The AAV2-Pep2hSC capsids are well suited for in vitro transductions of human and murine NF1 cells and direct injection of nerve segments. The AAV-SC3 capsid, derived from AAV9, is suitable for systemic injections in mouse models of NF1 when broad biodistribution and potentially blood-brain barrier (BBB) penetration is desired (AAV9 has broader biodistribution and ability to cross BBB in contrast to AAV2 (40)). AAV-SC3 had a similar biodistribution in the brain as compared to AAV9, thus, its inherent ability to cross the BBB does not seem to be compromised by the peptide insert. This is important as neurofibroma can affect the central nervous system (CNS) as well as the peripheral nervous system (PNS)(41). Finally, AAV-SC4 can be used for transduction of peripheral nerves as a prophylactic strategy for NF 1 and diseases of peripheral nerves, e.g., to deliver neurofibromin or a portion thereof as discussed above for NF 1, or peripheral myelin protein 22 (PMP22, Ref Seq NM_000304.4 (mRNA) or NP_000295.1 (protein)); gap junction protein beta 1 (GJB1, Ref Seq NM_000166.6 (mRNA) or NP_000157.1 (protein)); mitofusin 2 (MFN2, Ref Seq NM_014874.4 (mRNA) or NP_055689.1 (protein)); or myelin protein zero (MPZ, Ref Seq NM_000530.8 (mRNA) or NP_000521.2 (protein)) to treat a subject who has Charcot-Marie-Tooth.
[0063] AAV vectors, like other viruses and nanoparticles have a propensity to be biodistributed to the liver. Unless the liver is the target of therapy, this is generallyAtorney Docket No. 29539-0872WO1 / MGH 2025-338
[0064] undesirable as AAV transduction of liver has been associated with toxicity in both NHP studies and clinical trials (42, 43). In this study, biodistribution to and transduction of liver was assessed after systemic injection of AAV9 or AAV-SC3 both packaging the AAV-PO-tdT expression cassette. For both vectors, high levels of both biodistribution and transgene expression (assessed by RT-ddPCR and microscopy) to liver were observed. There was a small decrease in biodistribution to liver by AAV-SC3 compared to AAV9, but this may be insufficient for biologically relevant liver detargeting. It was also apparent that at the high doses of vector genomes observed in liver, the selectivity of the P0 promoter was lost, as robust expression in hepatocytes was evident by confocal microscopy. Thus, when using the AAV capsids described herein for peripheral (e.g., sciatic) nerve transduction after systemic administration, detargeting from the liver at the steps of both biodistribution and transduction can be used. For reducing off target expression in liver with SC-targeted AAV’s, incorporation of miRNA binding sites, such as those for miR122, have been successfully used (44, 45). Using SC-selective promoters and miRNA binding sites in the transgene expression cassette may increase the on-target expression in SCs as well as reduce off target expression.
[0065] Thus, described herein are new capsids, AAV-SC3 and AAV-SC4, that are useful in gene therapy approaches in NF1 as well as other peripheral nerve diseases.
[0066] Engineered AAV capsid proteins
[0067] The present methods identified two peptide sequences that alter the ability of an AAV to mediate transgene expression in specified cells when inserted into the capsid of the AAV, e.g., AAV1, AAV2, AAV8, or AAV9. In some embodiments, the peptides comprise sequences of at least 7 amino acids. In some embodiments, the amino acid sequence comprises at least 4, e.g., 5, 6, or all 7 contiguous amino acids of the following sequences:
[0068] Peptide Sequence SEQ ID NO:
[0069] AAV-SC3 RPDHLPP 3
[0070]
[0071] AAV-SC4 GATPSTQ 4
[0072] Peptides including reversed sequences can also be used, e.g., PPLHDPR (SEQ ID NO: 35) or QTSPTAG (SEQ ID NO: 36).Atorney Docket No. 29539-0872WO1 / MGH 2025-338
[0073] AAVs
[0074] Viral vectors for use in the present methods, kits and compositions include recombinant retroviruses, adenovirus, adeno-associated virus, alphavirus, and lentivirus, preferably comprising a capsid peptide as described herein and optionally a transgene for expression in a target tissue.
[0075] A preferred viral vector system useful for delivery of nucleic acids in the present methods is the adeno-associated virus (AAV). AAV is a tiny non-enveloped virus having a 25 nm capsid. No disease is known or has been shown to be associated with the wild type virus. AAV has a single-stranded DNA (ssDNA) genome. AAV has been shown to exhibit long-term episomal transgene expression, and AAV has demonstrated excellent transgene expression in the brain, particularly in neurons. Space for exogenous DNA is limited to about 4.7 kb. An AAV vector such as that described in Tratschin et al., Mol. Cell. Biol. 5:3251-3260 (1985) can be used to introduce DNA into cells. A variety of nucleic acids have been introduced into different cell types using AAV vectors (see for example Hermonat et al., Proc. Natl. Acad. Sci. USA 81:6466-6470 (1984); Tratschin et al., Mol. Cell. Biol. 4:2072-2081 (1985); Wondisford et al., Mol. Endocrinol. 2:32-39 (1988); Tratschin et al., J. Virol.
[0076] 51:611-619 (1984); and Flotte et al., J. Biol. Chem. 268:3781-3790 (1993). There are numerous alternative AAV variants (over 100 have been cloned), and AAV variants have been identified based on desirable characteristics. In some embodiments, the AAV is AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AV6.2, AAV7, AAV8, rh.8, AAV9, rh.10, rh.39, rh.43 or CSp3; for CNS use, in some embodiments the AAV is AAV1, AAV2, AAV4, AAV5, AAV6, AAV8, or AAV9. As one example, AAV9 has been shown to somewhat efficiently cross the blood-brain barrier. Using the present methods, the AAV capsid can be genetically engineered to increase permeation across the BBB, or into a specific tissue, by insertion of a peptide sequence as described herein into the capsid protein, e.g., into the AAV9 capsid protein VP1 between amino acids 588 and 589 or after amino acid 454, or in the VRIV loop.
[0077] An exemplary wild type AAV9 capsid protein VP1 (Q6JC40-1) sequence is as follows:
[0078] 10 20 30 40 50 MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY
[0079] 60 70 80 90 100Atorney Docket No. 29539-0872WO1 / MGH 2025-338
[0080] KYLGPGNGLD KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADAEF
[0081] 110 120 130 140 150 QERLKEDTSF GGNLGRAVFQ AKKRLLEPLG LVEEAAKTAP GKKRPVEQSP
[0082] 160 170 180 190 200 QEPDSSAGIG KSGAQPAKKR LNFGQTGDTE SVPDPQPIGE PPAAPSGVGS
[0083] 210 220 230 240 250 LTMASGGGAP VADNNEGADG VGSSSGNWHC DSQWLGDRVI TTSTRTWALP
[0084] 260 270 280 290 300 TYNNHLYKQI SNSTSGGSSN DNAYFGYSTP WGYFDFNRFH CHFSPRDWQR
[0085] 310 320 330 340 350 LINNNWGFRP KRLNFKLFNI QVKEVTDNNG VKTIANNLTS TVQVFTDSDY
[0086] 360 370 380 390 400 QLPYVLGSAH EGCLPPFPAD VFMIPQYGYL TLNDGSQAVG RSSFYCLEYF
[0087] 410 420 430 440 450 PSQMLRTGNN FQFSYEFENV PFHSSYAHSQ SLDRLMNPLI DQYLYYLSKT
[0088] 460 470 480 490 500 INGSGQNQQT LKFSVAGPSN MAVQGRNYIP GPSYRQQRVS TTVTQNNNSE
[0089] 510 520 530 540 550 FAWPGASSWA LNGRNSLMNP GPAMASHKEG EDRFFPLSGS LIFGKQGTGR
[0090] 560 570 580 590 600 DNVDADKVMI TNEEEIKTTN PVATESYGQV ATNHQSAQAQ AQTGWVQNQG
[0091] 610 620 630 640 650 ILPGMVWQDR DVYLQGPIWA KIPHTDGNFH PSPLMGGFGM KHPPPQILIK
[0092] 660 670 680 690 700 NTPVPADPPT AFNKDKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ
[0093] 710 720 730
[0094] YTSNYYKSNN VEFAVNTEGV YSEPRPIGTR YLTRNL (SEQ ID NO: 37 )
[0095] Thus provided herein are AAV that include one or more of the peptide sequences described herein, e.g., an AAV comprising a capsid protein comprising a sequence described herein, e.g., a capsid protein comprising SEQ ID NO:37, wherein a peptide sequence has been inserted into the sequence, e.g., between amino acids 588 and 589.
[0096] Exemplary sequences of AAVs are provided below. The inserted peptide sequences are bold and double-underlined highlighted in the protein sequences, and bold and capitalized in the DNA sequences.
[0097] The AAV sequences can be, e.g., at least 80, 85, 90, 95, 97, or 99% identical to a reference AAV sequence set forth herein, e.g., can include variants, preferable that do not reduce the ability of the AAV to mediate transgene expression in a cell. To determine the percent identity of two amino acid sequences, or of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps canAtorney Docket No. 29539-0872WO1 / MGH 2025-338
[0098] be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, the length of a reference sequence aligned for comparison purposes is at least 80% of the length of the reference sequence, and in some embodiments is at least 90% or 100%. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid “identity” is equivalent to amino acid or nucleic acid “homology”). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.
[0099] The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. For example, the percent identity between two amino acid sequences can determined using the Needleman and Wunsch ((1970) J. Mol. Biol. 48:444-453 ) algorithm which has been incorporated into the GAP program in the GCG software package (available on the world wide web at gcg.com), using the default parameters, e.g., a Blossum 62 scoring matrix with a gap penalty of 12, a gap extend penalty of 4, and a frameshift gap penalty of 5.
[0100] Transgenes
[0101] In some embodiments, the AAV also includes a transgene sequence (i.e., a heterologous sequence), e.g., a transgene encoding a therapeutic agent, e.g., as described herein or as known in the art, or a reporter protein, e.g., a fluorescent protein, an enzyme that catalyzes a reaction yielding a detectable product, or a cell surface antigen. The transgene is preferably linked to sequences that promote / drive expression of the transgene in the target tissue.
[0102] Other transgenes can include small or inhibitory nucleic acids that alter / reduce expression of a target gene, e.g., siRNA, shRNA, miRNA, antisense oligos, or long non-coding RNAs that alter gene expression (see, e.g., WO2012087983 and US20140142160), or CRISPR Cas9 / casl2a and guide RNAs.Atorney Docket No. 29539-0872WO1 / MGH 2025-338
[0103] The virus can also include one or more sequences that promote expression of a transgene, e.g. one or more promoter sequences; enhancer sequences, e.g. 5’ untranslated region (UTR) or a 3’ UTR; a polyadenylation site; and / or insulator sequences. In some embodiments, the promoter is a brain tissue specific promoter, e.g. a neuron-specific or glia-specific promoter. In certain embodiments, the promoter is a schwannoma-specific promoter selected from MPZ (Myelin Protein Zero, or P0 promoter) and PMP22 promoter (see, e.g., Ahmed et al., J Neurosci Methods. 2019 May 22;323:77-81, e.g., the supplementary section). In some embodiments, the promoter is a pan-cell type promoter, e.g., cytomegalovirus (CMV), beta glucuronidase, (GUSB), ubiquitin C (UBC), or rous sarcoma virus (RSV) promoter. Posttranscriptional regulatory elements can include HBV Posttranscriptional Regulatory Element (HPRE), woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) or variants thereof (e.g., WPRE2, WPRE3 see, e.g., Kalev-Zylinska ML, During MJJ Neurosci. 2007 Sep 26; 27(39): 10456-67; Zanta-Boussif et al., Gene Therapy (16): 605-619 (2009); Choi et al., Mol Brain. 7:17 (2014); US6136597).
[0104] In some embodiments, the AAV also has one or more additional mutations that increase delivery to the target tissue, e.g., the CNS, or that reduce off-tissue targeting, e.g., mutations that decrease liver delivery when CNS, heart, or muscle delivery is intended (e.g., as described in Pulicherla et al. (2011) Mol Ther 19:1070-1078); or the addition of other peptides, e.g., as described in Chen et al. (2008) Nat Med 15:1215- 1218 or Xu et al., (2005) Virology 341:203-214 orUS9102949; US 9585971; and US20170166926. See also Gray and Samulski (2011) “Vector design and considerations for CNS applications,” in Gene Vector Design and Application to Treat Nervous System Disorders ed. Glorioso J., editor. (Washington, DC: Society for Neuroscience; ) 1-9, available at sfn.org / ~ / media / SfN / Documents / Short%20Courses / 2011%20Short%20Course%20I / 2011_SCl_Gray.ashx.
[0105] Methods of Use
[0106] The methods and compositions described herein can be used to deliver any composition, e.g., a sequence of interest to a tissue, e.g., to a neurofibroma or to the peripheral nervous system, after local or systemic administration. In some embodiments, the methods include delivery to a neurofibroma, e.g., a peripheral neurofibroma or neurofibroma in the spinal cord, brain, e.g., in the cortex, cerebellum,Atorney Docket No. 29539-0872WO1 / MGH 2025-338
[0107] hippocampus, substantia nigra, or amygdala. In some embodiments, the methods include delivery to the brain or lumbar delivery, e.g., into the subarachnoid space or epidural space. In some embodiments, the methods include systemic delivery, e.g., via intravenous, intraarterial, subcutaneous, intraperitoneal, intrathecal, intramuscular, or other injection or infusion.
[0108] In some embodiments, the methods and compositions, e.g., AAVs, are used to deliver a nucleic acid sequence to a subject who has a disease, e.g., Neurofibromatosis type 1 (NF1) or NF2. In some embodiments, the subject has (has been diagnosed with) NF 1 or NF2, and the vectors are used to deliver a therapeutic agent for treating NF1 orNF2, respectively.
[0109] In some embodiments, the subject has NF1, and the therapeutic agent for treating NF 1 comprises a sequence encoding 333 amino acids of the GAP-related domain (GRD) of neurofibromin (NF1 1200-1532 AA), optionally with both N- and C-terminal Spredl -binding sequences at its N- and C-terminus (see Hirata et al., J. Biol. Chem. 291:3124-3134 (2016)); in some embodiments, the agent is membrane-targeted, truncated neurofibromin comprising the GAP-related domain (GRD) fused to the C-terminal 10 AA of HRAS domain (CIO), the C-terminal 24 AA of KRAS4B (C24), or another similar RAS C-terminal domain (see Bai et al., Nat Commun. 2025 Sep 29; 16(1):8594). The therapeutic agent can be delivered as a nucleic acid, e.g., via a viral vector, wherein the nucleic acid encodes a therapeutic protein or other nucleic acid such as an antisense oligo, siRNA, shRNA, and so on.
[0110] An exemplary sequence of GAP-related domain (GRD) of human neurofibromin is the following:
[0111] ETVLADRFERLVELVTMMGDQGELPIAMALANWPCSQWDELARVLVTLFDSRHLLY QLLWNMFSKEVELADSMQTLFRGNSLASKIMTFCFKVYGATYLQKLLDPLLRIVITS SDWQHVSFEVDPTRLEPSESLEENQRNLLQMTEKFFHAI ISSSSEFPPQLRSVCHCL YQATCHSLLNKATVKEKKENKKSWSQRFPQNS IGAVGSAMFLRFINPAIVSPYEAG ILDKKPPPRIERGLKLMSKILQS IANHVLFTKEEHMRPFNDFVKSNFDAARRFFLDI ASDCPTSDAVNHSLSFISDGNVLALHRLLWNNQEKIGQYLSSNRDHKAVGRRPFDKM ATLLAYLGPPEH (SEQ ID NO: 38 )
[0112] In some embodiments, the subject has NF2, and the therapeutic agent is selected from caspase- 1 (interleukin-P-converting enzyme; ICE), the pore-forming protein Gasdermin-D, apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), functional merlin (the protein product of the NF2 gene),Atorney Docket No. 29539-0872WO1 / MGH 2025-338
[0113] and CRISPR-associated protein 9 (CRISPR / Cas9) base editor with a guide RNA (gRNA) directing the base editor to correct point mutations in the NF2 gene (46-52; see also WO2022 / 221447).
[0114] The methods and compositions described herein can be used to treat these conditions in a subject in need thereof, by administration of a therapeutically effective amount of an AAV carrying a therapeutic transgene, sufficient to ameliorate, reduce risk of, or delay onset of one or more symptoms of the condition. In some embodiments, the AAV is administered systemically. In subjects with NF 1 orNF2, the AAV can be administered locally to a neurofibroma, or to the brain or spinal cord, depending on the location of the neurofibroma.
[0115] The methods described herein include the use of pharmaceutical compositions comprising the AAVs as an active ingredient.
[0116] Pharmaceutical compositions typically include a pharmaceutically acceptable carrier. As used herein the language “pharmaceutically acceptable carrier” includes saline, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration.
[0117] Pharmaceutical compositions are typically formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intraarterial, subcutaneous, intraperitoneal, intrathecal, intramuscular, or injection or infusion administration. Delivery can thus be systemic or localized.
[0118] Methods of formulating suitable pharmaceutical compositions are known in the art, see, e.g., Remington: The Science and Practice of Pharmacy, 21st ed., 2005; and the books in the series Drugs and the Pharmaceutical Sciences: a Series of Textbooks and Monographs (Dekker, NY). For example, solutions or suspensions used for parenteral application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloricAtorney Docket No. 29539-0872WO1 / MGH 2025-338
[0119] acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
[0120] Pharmaceutical compositions suitable for injectable use can include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyetheylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, aluminum monostearate and gelatin.
[0121] Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.
[0122] Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle, which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying, which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
[0123] In one embodiment, the therapeutic compounds are prepared with carriers that will protect the therapeutic compounds against rapid elimination from the body, suchAtorney Docket No. 29539-0872WO1 / MGH 2025-338
[0124] as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Such formulations can be prepared using standard techniques, or obtained commercially, e.g., from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to selected cells with monoclonal antibodies to cellular antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.
[0125] The pharmaceutical compositions can be included in a kit, container, pack, or dispenser together with instructions for administration. For example, the kit can include compositions comprising an AAV comprising a peptide as described herein.
[0126] EXAMPLES
[0127] The invention is further described in the following examples, which do not limit the scope of the invention described in the claims.
[0128] MATERIALS AND METHODS
[0129] The following methods and materials were used in the Examples below, unless otherwise specified.
[0130] Cells. Human 293 T cell were obtained directly from American Type Culture Collection (CRL, 3216, Manassas, VA) and a large cryo-bank was made. Cells (passage 30 and below) were cultured in high glucose Dulbecco’s modified Eagle’s medium containing HEPES (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS) (Sigma, St. Louis, MO) and lx Gibco Penicillin-Streptomycin-Glutamine (100 U / mL penicillin, 100 pg / mL streptomycin, 292 pg / mL L-glutamine (Invitrogen) in a humidified atmosphere supplemented with 5% CO2 at 37 °C. Cells were tested and confirmed negative for mycoplasma contamination using a MycoAlert® kit (Lonza).
[0131] Animals. All animal experiments were approved by the Massachusetts General Hospital Subcommittee on Research Animal Care following guidelines set forth by the National Institutes of Health Guide for the Care and Use of Laboratory Animals. We used adult age (8-10 week old) female C57BL / 6 (strain # 000664) from The Jackson Laboratory (Bar Harbor, ME). No sample size calculation was performedAttorney Docket No. 29539-0872WO1 / MGH 2025-338
[0132] for the experiments. Sample sizes were chosen based on prior experiments which yielded statistically significant differences between groups. For all animal studies, investigators assigned to perform analysis of tissues were blinded to the group identity. The principal investigator held the key to the codes and the samples were unblinded at the time of graphing the data.
[0133] The NF 1 floxed animal model was a gift from Dr. Luis Parada, UT Southwestern Medical Center, Dallas, TX with exons 31-32 of Nfl gene flanked by loxP sites provided by Dr. Nancy Ratner(13). The luciferase reporter mouse strain was contributed by Dr. Alain Charest, Beth Israel Deaconess Medical Center, Boston, MA. This animal model has a loxP -flanked STOP cassette upstream of the luciferase cDNA(14). Nflflox / flox / Flucfloxanimal model was generated by mating the NflI,II l,oxand Flucflox / ' mice with each other and genotyping of progeny.
[0134] Nflflox / flox / FlUCflox littermates were identified by tail genotyping using two sets of PCRs, targeting Nfl and luciferase genes, respectively. First PCR was used to amplify the Nfl gene at two sites : a 480-bp band [from intron 30 of the Nfl gene of the wild-type (WT) allele] and a 350-bp band (from the neo gene of the floxed allele; for details refer to Table 1 ). Conditions for genotyping were 94°C for 1 min followed by 30 cycles of 94°C for 30s, 65°C for 30s and 72°C for 60s and ending with an extension for 2 min at 72°C using primers targeting Nfl (Table 1). Another PCR was performed to detect the presence of the floxed luciferase transgene. Conditions for genotyping were 95°C for 5 min followed by 40 cycles of 94°C for 30s, 55°C for 30s and 72°C for 30s and ending with an extension for 10 min at 72°C using primers in Table 1
[0135] For animal studies using C57BL / 6 mice, mice were randomly grouped. For the Nflflox / flox / Flucfloxmice used in the studies with vectors targeting NF1 neurofibroma, mice were grouped according to the bioluminescent signal from the AAVl-Cre injected nerve(s) as described in the section “Transduction and biodistribution study in the murine NF1 model”.
[0136] Table 1. List of primers used.
[0137] Ana- Gene § Forward primer Reverse primer Probe
[0138] lysis j (5’ to 3’)
[0139] PCR | pUC57-lib 5 AGCTACCGACAA AGAAGGGTGAAAGTT j
[0140] I sub cl one | CAACGTGT GCCGT
[0141]
[0142] i (SEQ ID NO: 39) (SEQ ID N():40)Attorney Docket No. 29539-0872WO1 / MGH 2025-338
[0143] Library NGS AACTACTAACCC GTGCTTCATTCCAAA - GGTAGCAA CCCTC
[0144] (SEQ ID NO:41) (SEQ IDNO:42)
[0145] Nfl gene CTTCAGACTGAT ACCTCTCTAGAATCA - (WT allele) TGTTGTACCTGA GGAATG
[0146] (SEQ ID NO:43) (SEQ IDNO:44)
[0147] Nfl gene CTTCAGACTGAT TGATTCCCACTTTGTG - (flox allele) TGTTGTACCTGA GTTCTAAG
[0148] (SEQ ID NO:45) (SEQ IDNO:46)
[0149] Luciferase CTGCATAAGGCT GAGGAGTTCATGATC - ATGAAGAG AGTGC
[0150] (SEQ ID NO:47) (SEQ IDNO:48)
[0151] qPCR tdTomato TGATGGACCTGTG GCCTGGTGGATTTCTCC CGGTGGAGGCCTCC and (codon ATGCAGA TTTC CATCCCA
[0152] RT- diversified, (SEQ ID NO:49) (SEQ IDNO:50) (SEQ IDNO:51) ddPC Addgene
[0153] R 59462
[0154] plasmid
[0155]
[0156] derived seq)
[0157] AAV peptide display library production
[0158] We have previously described construction and production of the iTransduce AAV9 peptide display library (11).
[0159] AAV-PO-tdTomato (tdT) expression cassette and AAV-CAP.NF rep / cap plasmid construction
[0160] To generate an AAV expression cassette driving tdT under the PO promoter we used pAAV-CAG-tdT (codon diversified), a gift from Edward Boyden (Addgene plasmid # 59462; http: / / n2t.nct / addgene:59462; RRID:Addgene_59462). We removed the CAG promoter / elements using an upstream Ndel site and downstream Kpnl site (upstream of tdT cDNA). Next, we PCR-amplified a fragment of rat PO promoter (Q5 enzyme, NEB, Ipswich, MA) from dsAAV-PO-GFP plasmid(15) using the following primers which both contain sequences homologous to pAAV-CAG-tdT for Gibson Assembly:
[0161] Gibson Rat PO For: 5’-tgcccacttggcagtacatcaagtgtatcatatgacgagcattctcgaactct- 3’ (SEQ ID NO: 52)
[0162] Gibson Rat PO Rev: 5’-cctcgcccttactcaccatggtggcggtacccagagcgtctgtggggt-3’ (SEQ ID NO:53)
[0163] We next performed a Gibson Assembly reaction (NEB) with the digested AAV-tdT plasmid and PO promoter PCR product with homology arms andAtorney Docket No. 29539-0872WO1 / MGH 2025-338
[0164] transformed an aliquot of the assembly into SURE electrocompetent bacteria (Agilent, Santa Clara, CA). Bacterial clones were screened by Smal restriction enzyme digestion to evaluate inverted terminal repeat (ITR) integrity. Next, we performed complete plasmid sequencing to confirm sequence integrity using Oxford Nanopore technology at Plasmidsaurus (Eugene, OR).
[0165] To create a rep / cap plasmid encoding AAV9 capsids displaying the peptide inserts of interest for production of vectors encoding AAV-PO-tdTomato, we digested an AAV9 rep / cap plasmid with BsiWI and Bael which removed a fragment flanking the VP3 amino acid 588 site for peptide sequence insertion. Next, we ordered a 997 bp dsDNA fragment from Integrated DNA Technologies (IDT, Coralville, IA), which contains overlapping Gibson homology arms with the BsiWI / Bael cut AAV9 as well as the 21-mer nucleotide sequence encoding the peptide of interest in frame after amino acid 588 of VP3. Last, we performed Gibson assembly using the Gibson Assembly® Master Mix (NEB) to ligate the peptide containing insert into the AAV9 rep / cap plasmid. Insert identification was confirmed by complete plasmid sequencing as above.
[0166] AAV vector production, purification, and titration
[0167] For transgene expression studies we used pAAV-PO-tdT plasmid described above. AAV production was performed, as previously described(16). Briefly, 293T cells were triple transfected using polyethylenimine reagent with (1) rep / cap plasmid (AAV9, AAV-F, AAV-SC3, or AAV-SC4) (2) an adenovirus helper plasmid, pAdAF6, and (3) ITR-flanked AAV-PO-tdT transgene expression plasmid. Cell lysates were harvested 68-72 h post-transfection and purified by ultracentrifugation in an iodixanol density gradient. lodixanol was removed and buffer exchanged to phosphate buffered saline (PBS) containing 0.001% Pluronic F68 (Gibco, Thermo Fisher Scientific, Waltham, MA) using 7 kDa molecular weight cutoff Zeba™ desalting columns (Thermo Fisher Scientific). Vector was concentrated using Amicon® Ultra-2 100 kDa MWCO ultrafiltration devices (Millipore Sigma, St.
[0168] Louis, MO). Vector titers in vector genome (vg) / ml were determined by Taqman qPCR in an ABI Fast 7500 Real-time PCR system (Applied Biosystems, Foster City, CA) using custom probes and primers to the tdT sequence (Table 1) and interpolated from a standard curve made with a restriction enzyme-linearized AAV plasmid.
[0169] Vectors were pipetted into single-use aliquots and stored at -80°C until use.Atorney Docket No. 29539-0872WO1 / MGH 2025-338
[0170] Barcoded AAV capsid candidate production for screening in C57BL / 6 mouse sciatic nerve.
[0171] We individually packed the AAV-CBA-hFrataxin barcoded genome described in (17) in each capsid candidate (AAV-SC1 to SC4, Table 2) and the AAV9 capsid. Vectors were produced, purified and titered as described above.
[0172] Bioluminescence imaging of neurofibroma progression
[0173] To induce neurofibroma formation, sciatic nerves were directly injected with AAVl-CAG-Cre vector. To visualize tumor growth in the sciatic nerve, the animals were first anesthetized with isoflurane and then injected intraperitoneally with d-luciferin (150 pg / g body weight; GoldBio Technology, St. Louis, MO). Five minutes after the injection of d-luciferin, imaging was performed using an IVIS® Spectrum optical imaging system fitted with an XGI-8 Gas Anesthesia System (Perkin Elmer, Hopkinton, MA). Bioluminescent images were acquired using the auto-exposure function. Data analysis for signal intensities and image comparisons were performed using Living Image® software (Perkin Elmer). To calculate radiance for each animal, regions of interest (ROI) were carefully drawn around each signal which is expressed as radiance (photons / sec / cm2 / steradian).
[0174] Hematoxylin and eosin (H&E) and immunohistochemistry (IHC) staining for neurofibroma
[0175] Mice were transcardially perfused with IX PBS. Neurofibroma and naive sciatic nerves were harvested, fixed in 10% formalin overnight and then embedded in paraffin. H&E staining was performed on deparaffinized and rehydrated tissue 5 pm thick tissue sections with established standard protocol (DFHCC Special Core at MGH). To further characterize this tumor, we performed IHC staining for SC marker SoxlO (Cat no. 66786, Proteintech, Rosemont, IL) and proliferative marker Ki67 (Cat no 790-4286, Ventana Medical Systems, Oro Valley, AZ). For SoxlO and Ki67 staining, tissue sections were deparaffinized, rehydrated, and then subjected to antigen retrieval using established protocol (DFHCC Special Histology core in MGH).
[0176] Tissues were blocked by 10% goat serum in PBS before immunostaining staining using 3, 3 '-diaminobenzidine (DAB), according to manufacturer's protocol with the HRP-conjugated anti -rabbit ( K4010 Kit, Dako Single Stain Envision Kits, Carpinteria, CA).Atorney Docket No. 29539-0872WO1 / MGH 2025-338
[0177] In vivo selection of SC-tropic capsids
[0178] We performed two rounds of in vivo selection to identify our candidate capsids. For round one, we injected the Nflflox / flox / Flucfloxneurofibroma-bearing mice (n=2) with the unselected AAV peptide library via tail vein i.v. injection at a dose of 4xlO10vg / mouse. Two weeks post-injection, the sciatic nerve with neurofibroma and the contralateral side (naive nerve) were harvested for DNA isolation. We recovered cap gene sequences via PCR from both neurofibromas and the naive nerves. DNA was isolated using the Arcturus PicoPure DNA Extraction Kit (Applied Biosystems; Cat no.: 11815-00). Then, AAV vector DNA corresponding to the 21-mer insertcontaining region was amplified by PCR using Q5® High-Fidelity DNA Polymerase (New England Biolabs, cat no: M0491, Ipswich, MA) and Library NGS primers (Table l).We then pooled the PCR amplified cap gene containing the inserts extracted from the neurofibroma samples and cloned them into the AAV plasmid backbone to produce vector for round two.
[0179] For the second round of selection, we injected Nfl1,IIX 1,llx / Flucl,llx I,IIneurofibroma-bearing mice (n=2) with the library generated from round 1 at a dose of 1.15xl010vg / mouse, via the tail vein. Two weeks post-injection, the animals were euthanized, and sciatic nerves were harvested.
[0180] Unique barcode adapters were annealed to each sample, and samples were sequenced on an Illumina MiSeq. Approximately 100,000 reads per sample were analyzed. Sequence output files were quality checked initially using FastQC (http: / / www.bioinformatics.babraham.ac.uk / projects / fastqc / ) and analyzed using a program custom written in Python. Briefly, sequences were binned based on the presence or absence of insert; insert-containing sequences were then compared to a baseline reference sequence (AAV9-VP3), and error-free reads were tabulated based on incidences of each detected unique 21-mer insert. 21-mer inserts were translated into peptides and normalized.
[0181] Transduction and biodistribution study in the murine NF1 model Seventeen Nflflox / flox / Flucfloxmice (both sexes were included) were injected with AAVl-CBA-Cre (CBA= chicken beta-actin promoter) vector into both sciatic nerves at the sciatic notch (34 nerves total). Mice were imaged by bioluminescence imaging as described above and 34 days later separated into four groups (one novector group, n=2; AAV9, n=5; AAV-F, n=5; AAV-SC3, n=5). This experiment wasAtorney Docket No. 29539-0872WO1 / MGH 2025-338
[0182] performed once. Animal allocation into groups: we measured the bioluminescence signal in sciatic nerves for each mouse and grouped mice such that each group had an equal number of males and females and the mean bioluminescence signal for each group was within 2-fold of the other groups. Mice were then injected with 1012vg of each capsid packaging the AAV-PO-tdT genome via the tail vein. Six weeks later, mice were euthanized, and one sciatic nerve was harvested and snap frozen for RT-digital droplet (dd)PCR analysis. The other sciatic nerve was drop-fixed in buffered 3.7% formaldehyde and then cryoprotected and embedded in O.C.T. media (Tissue TEK, Sakura Finetek USA, Torrance, CA) for cryosectioning. We also snap froze brain and liver from each mouse for qPCR biodistribution of AAV genomes. All groups and samples were coded and individuals running the assays below were blinded to the sample identities.
[0183] Transduction and biodistribution studies in adult C57BL / 6 mice
[0184] For comparison of AAV9 to AAV-SC4 we used n=6 mice / group (both sexes were included, 3 males, 3 females). Mice were then injected via the tail vein with 1012vg (~5xl013vg / kg) of each capsid packaging the AAV-PO-tdT genome. Seven weeks later, mice were euthanized, and one sciatic nerve was harvested and snap frozen for RT-ddPCR and qPCR analysis. The other sciatic nerve was drop-fixed in buffered 3.7% formaldehyde and then cryoprotected and embedded in O.C.T. media (Tissue TEK, Sakura Finetek USA, Torrance, CA) for cryosectioning. All groups and samples were coded and individuals running the assays below were blinded to the sample identities. For testing transduction of liver and sciatic nerve with AAV-SC4 capsid packaging a self-complementary (sc) CAG-GFP expression cassette, we injected n=3 adult female C57BL / 6 mice with a dose of IxlO11vg (~5xl012vg) of vector via the tail vein. Three weeks later, mice were euthanized and liver and sciatic nerves harvested for immunofluorescence microscopy analysis of cryosections. This experiment was performed one time.
[0185] Taqman real-time qPCR for AAV genome biodistribution in brain, liver, and sciatic nerve
[0186] AAV vgs and murine genomes were co-isolated from homogenized brain, liver, and sciatic nerve tissue using a DNeasy Blood and tissue kit (Qiagen, 69504, Germantown, MD). Briefly, approximately 10 mg tissue was homogenized using 1.4 mm ceramic beads and buffer ATL (Qiagen) in a BeadBug™ homogenizerAtorney Docket No. 29539-0872WO1 / MGH 2025-338
[0187] (Benchmark Scientific, Sayreville, NJ). Following homogenization, we followed the manufacturer’s protocol to isolate DNA. DNA concentrations were determined using a NanoDrop spectrophotometer (Thermo Fisher Scientific). All samples were diluted to 100 ng / pl and 1 pl of sample was used for a Taqman qPCR in an ABI Fast 7500 Real-time PCR system (Applied Biosystems) using probes and primers to the tdT sequence (Table 1) and interpolated from a standard curve made with a restriction enzyme-linearized AAV plasmid. We quantitated the amount of AAV genomes in each sample by converting the vg copies in each reaction (1 ng input DNA) to AAV genomes per pg of input DNA.
[0188] RNA extraction, cDNA synthesis and ddPCR to detect AAV transduction of neurofibroma and naive sciatic nerves
[0189] Total RNA from sciatic nerves was extracted using the Qiagen miRNeasy Micro Kit (catalog no. 217084), and an additional DNase digestion was performed using the Qiagen RNase-free DNase set (catalog no. 79254) to ensure AAV-tdT genomic DNA digestion. Complementary DNA (cDNA) was synthesized consistently for all samples, using the SuperScript IV VILO cDNA Synthesis Master Mix (Thermo Fisher Scientific, catalog no. 11756050), according to the manufacturer’s protocol.
[0190] Absolute quantification of target transcripts (copies / pl) was determined using the Automated Droplet Generator QX200 AutoDG Droplet Digital System from BioRad (Hercules, CA), according to the manufacturer’s instructions. The TaqMan PCR reaction mixture consists of ddPCR Supermix for Probes (No dUTP) (Bio-Rad catalog no.1863024), primers, probes and template cDNA (3 ng / pL) in a final volume of 20 pL. TaqMan probe and primers were used for tdT (codon diversified, Addgene 59462 plasmid derived seq.; forward primer, 5’ - TGATGGACCTGTGATGCAGA -3’ (SEQ ID NO: 54); reverse primer, 5’ - GCCTGGTGGATTTCTCCTTTC -3’ (SEQ IDNO:55); probe, 5’ -CGGTGGAGGCCTCCCATCCCA-3’ (SEQ ID NO:56)) peptidylprolyl isomerase A (PPIA) (Mm02342430_gl), and GAPDH (Hs02786624_gl). Each assembled ddPCR reaction mixture was then loaded into the sample wells of an eight-channel disposable droplet DG32 Cartridge for QX200 (BioRad, catalog no.1864108). A volume of 20 pL of droplet generation oil (Bio-Rad catalog no. 1864110) was loaded into the oil well for each channel. The plate was heat sealed with a foil seal and then placed on a conventional thermal cycler and amplified to the end point, according to the manufacturer’s cycling conditions. After PCR, theAtorney Docket No. 29539-0872WO1 / MGH 2025-338
[0191] 96-well PCR plate was loaded on the droplet reader (Bio-Rad) and analysis of the data was performed with QuantaSoft analysis software (Bio-Rad). Tdt expression in neurofibroma was normalized to readings for PPIA, a reference gene previously used for nerve samples(18), and expression in naive sciatic nerve was normalized to GAPDH.
[0192] Immunofluorescence analysis of neurofibroma and naive sciatic nerve in mice injected i.v. with AAV vectors
[0193] Sciatic nerves from mice with neurofibroma were post-fixed in 4% formaldehyde diluted in PBS for 48 h, followed by 30% (w / v) sucrose for
[0194] cry opreservation for another 48-72 h after which nerves were embedded and frozen in Tissue-Tek ® O.C.T. compound (Fisher Scientific). Sections (10 pm) were cut using a NX50 CryoStar Cryostat (Thermo Scientific) and mounted on glass slides for immunostaining. For immunofluorescence, the cryosections were permeabilized with 0.5% v / v Triton™ X-100 (Millipore Sigma) in PBS for 30 min and blocked with 5% v / v normal chicken serum (NCS) in PBS for 1 h. We treated sections with TrueBlack® Lipofuscin Autofluorescence Quencher (Biotium, Fremont, CA) to reduce neurofibroma autofluorescence. Tissue sections were incubated with primary antibody diluted in 1.5% v / v NCS at 4°C for 48 h. After three washes with PBS, coronal sections and secondary antibodies diluted in 1.5% v / v NCS were incubated for 1 h at RT. For staining of tdT and Sox 10 we used chicken anti-mCherry (cat. MCHERRY-002; Aves Labs, Davis, CA) at a dilution of 1:200 and rabbit anti-SOXlO at a dilution of 1:100 (cat. no. AB227680; Abeam, Waltham, MA). Secondary antibodies (both at 1:350 working dilution) were goat anti-chicken Alexa594 and goat anti-rabbit-Alexa647 (both from ThermoFisher). For GFP immunostaining we used Chicken anti-GFP antibody (GFP 1020, Aves Labs) at a dilution of 1:500.
[0195] Slides were cover slipped with Vectashield mounting medium with DAPI (Vector Laboratories, Burlingame, CA) and imaging was performed with a NIKON CSU-W1 spinning disk confocal microscope.
[0196] Candidate pooled barcoded library screen in adult mice.
[0197] Three adult male C57BL / 6 mice were intravenously injected with 7.OxlOlovg of the five pooled, barcoded capsids (1.4xlO10vg / capsid). Two weeks later, deeply anesthetized animals were perfused with cold PBS. We harvested sciatic nerves, brain, liver, and heart from each animal. Samples for DNA extraction wereAtorney Docket No. 29539-0872WO1 / MGH 2025-338
[0198] immediately frozen on dry ice and stored at -80°C. This experiment was performed once.
[0199] DNA isolation from mice for barcoded AAV capsid candidates.
[0200] Tissue samples (~25 mg) were homogenized using 1.4 mm ceramic beads in a BeadBug tissue homogenizer (Benchmark Scientific) in buffer ATL of the DNeasy Blood and Tissue Kit (Qiagen). After homogenization, we followed the manufacturer’s instructions to purify DNA. DNA concentration was determined using a NanoDrop spectrophotometer (ThermoFisher Scientific).
[0201] Transduction and biodistribution study in C57BL / 6 mice of AAV9 vs AAV-SC3
[0202] Twelve adult 8-10 week old C57BL / 6 male mice were separated into three groups (no-vector group, n=2; AAV9, n=5; AAV-SC3, n=5). Mice were injected with 1012vg of each capsid packaging the AAV-PO-tdT genome via the tail vein. Seven weeks later, mice were euthanized and the left sciatic nerve upper half was harvested and snap frozen for vector genome biodistribution and the lower half for RT-ddPCR analysis. The right sciatic nerve was drop-fixed in buffered 3.7% formaldehyde and then cryoprotected and embedded in O.C.T. media (Tissue TEK, Sakura Finetek USA, Torrance, CA) for cryosectioning. We also harvested the liver from each mouse for qPCR biodistribution of AAV genomes, RT-ddPCR analysis and immunostaining. All groups and samples were coded and individuals running the assays below were blinded to the sample identities.
[0203] PCR to amplify barcodes for NGS.
[0204] A PCR using the DNeasy-purified DNA as template was performed (150 ng DNA template input). We used Q5 polymerase (NEB) and primers that amplify a 182bp amplicon which contains the unique barcode for each capsid. Primers were: SC-Lib-Fwd (5’ GATGCTTACCCTTACGACGT 3’ (SEQ ID NO:57)) and SC-Lib-Rev (5’ CAGCGTATCCACATAGCGTA 3’ (SEQ ID NO:58)). The PCR product was purified using the QIAquick PCR purification kit (Qiagen) and samples were submitted for NGS as described above. We initially sequenced an aliquot of the preinjected pooled barcoded AAV capsids to ascertain the precise frequencies of the barcoded variants on input. Output frequencies in all tissues were normalized to these initial ratios. Insert-containing sequence reads were binned using Hamming distance,Atorney Docket No. 29539-0872WO1 / MGH 2025-338
[0205] comparing to the known barcode sequences; additional quality control was undertaken to ensure only true barcoded reads were assigned to each capsid.
[0206] Statistics.
[0207] We used GraphPad Prism 10.3.1 for PC for statistical analysis. For comparison of AAV barcoded genome frequency between capsids and across tissues we used a 2-way ANOVA followed by a Dunnett’s multiple comparisons test. For comparison of biodistribution or transduction of a single tissue between three capsids we used an Ordinary one-way ANOVA followed by a Dunnett’s multiple comparisons test. For comparison of two capsids for biodistribution to or transduction of sciatic nerve we used an unpaired two-tailed t test, p values <0.05 were accepted as significant.
[0208] Example 1. M'lllovllo'7Fluc11"' induced mouse tumor model with characteristics of neurofibroma
[0209] We used Nfl-flox / flox (off) transgenic mice(19) crossed to Fluc-flox (on) mice(14). We injected AAVl-CBA-Cre into the left sciatic nerve of young adult mice (total dosage of 6xlO10vg / mouse), such that Cre knocked out Nfl function, through the use of conditional (Cre / lox) alleles and turned on luciferase (which has a floxed STOP cassette) (Fig. la). This injection into the sciatic nerve could have produced minor injury to the nerve, with nerve injury being associated with NF 1 -null neurofibroma formation(20, 21). The right sciatic nerve was not injected and termed the naive nerve. Using in vivo bioluminescence imaging, firefly luciferase (Flue) activity was detected on the left sciatic nerve indicating tumor formation, beginning 2 weeks post-injection (Fig. lb; n=9). Five weeks post-injection, we observed increased tumor growth (increased luciferase activity) on the left sciatic nerve up to the 13thweek post-injection. Naive nerves and those bearing neurofibroma were harvested for further characterization. Gross anatomical assessment indicated that the tumorbearing sciatic nerve (Nfl' / _) was markedly thickened and highly vascularized as compared to the contralateral naive nerve (Nfl+ / +; Fig. lb, inset). Histopathological examination confirmed features of neurofibroma, such as hypercellularity, expansion of the nerve, presence of mast cells, mixed composition of SCs and fibroblasts, consistent with early neurofibroma formation (Fig. 1c). Immunohistochemical analysis showed that the neurofibroma had many SCs, as indicated by Sox 10 immunoreactivity (Fig. Id). Scattered proliferating cells highlighted by Ki67Atorney Docket No. 29539-0872WO1 / MGH 2025-338
[0210] expression are associated with a neurofibroma (Fig. le). Taken together, both the histological and molecular characteristics of the tumor from the AAVl-Cre injected sciatic nerve were consistent with those of neurofibroma.
[0211] Example 2. In vivo selection in the neurofibroma model identified AAV capsids that traffic to the tumor after systemic injection
[0212] As previously described(l 1) AAV97-mer peptide-display library was produced by transfection of 293T cells with the library plasmids. Before library production, the plasmid library was sequenced via next generation sequencing (NGS) and confirmed the presence of 21-mer inserts (coding for 7-mer peptides) and lack of variant bias. We then packaged the capsid library, performed NGS and confirmed that the vector creation process maintained sufficient diversity (based on experience with prior successful selections, (11, 17)).
[0213] To perform the selection, we injected the Nflflox / flox / Flucfloxneurofibromabearing mice (n=2) with the AAV peptide library via tail vein i.v. injection at a dosage of 4xlO10vg / mouse. Two consecutive rounds of selection were performed, with the composition of the viral pool assessed at each round by next generation sequencing (NGS) (Fig. 2a). Two weeks post-injection, the sciatic nerve with neurofibroma and its equivalent contralateral side (naive nerve) were harvested for DNA isolation and purification. We recovered cap gene sequences via PCR from both neurofibromas and one of the naive nerves. We found numerous 7-mer variants were enriched in sciatic nerves. We then pooled the PCR amplified cap gene containing the inserts extracted from the neurofibroma samples and cloned them into the AAV plasmid backbone to produce vector for round two.
[0214] For the second round of selection, we injected two Nflflox / flox / Flucfloxneurofibroma-bearing mice with the library generated from round 1 at a dose of 1.15xlO10vg / mouse, via the tail vein. Two weeks post-injection, the animals were euthanized, and sciatic nerves were harvested. We recovered variants from both neurofibromas (n=2) and naive nerve (n=2) and subjected the resulting PCR amplicons separately for NGS. Peptide sequences encoded by the 21-mer inserts in cap for each of the four samples are shown (Fig. 2b). We compared the profile from each nerve / neurofibroma and chose one variant, RPDHLPP (called AAV-SC3) to test further as it was found at similar frequency (3.4 to 4.3%) in both mice in the neurofibroma, but not the naive sciatic nerve (Fig. 2b).Atorney Docket No. 29539-0872WO1 / MGH 2025-338
[0215] Example 3. AAV-SC3 transduces neurofibroma after systemic injection of mice
[0216] To ascertain if AAV-SC3 had higher efficiency at neurofibroma targeting than the parental AAV9 capsid, we constructed an AAV expression plasmid which encodes tdT under the rat P0 promoter. This promoter was used to restrict expression to SCs for two main reasons. First, it allows more specific expressing thus preventing confounding results in quantitative PCR and imaging assays, such as transduced neurons and their axons in the sciatic nerve. Second, using the P0 promoter should be safer than a more ubiquitous promoter when developing a therapeutic to treat neurofibroma. Expressing the transgene in target (SCs) vs non-target cells (e.g. liver) may prevent off-target toxicity observed with transgene overexpression(22). The AAV construct is shown in Figure 3a. We also included another capsid, AAV-F, which was originally identified by its high efficiency of crossing the blood-brain barrier in mice(l 1, 23, 24) and subsequently we observed transduction of sciatic nerve after intrathecal injection in non -human primates(25).
[0217] Nflflox / flox / Flucfloxmice were injected in both sciatic nerves with 1010vg of AAVl-Cre to induce two neurofibromas / mouse. After 34 days, mice (n=5 / group) received systemic injections of 1012vg of AAV9-P0-tdT, AAV-F-PO-tdT, or AAV-SC3— PO-tdT and 6 weeks later tissues were harvested. From each mouse, one neurofibroma was used to quantitate tdT expression at the mRNA level by RT-ddPCR and the other was post-fixed in formaldehyde, cryoprotected, and sectioned for immunofluorescence analysis. We also analyzed the biodistribution of each capsid’s packaged genomes in brain and liver using qPCR with specific probes and primers to detect the tdT DNA. We observed that one of the animals injected with AAV-SC3 had a 100-fold decrease in vgs compared to all other mice in the group (data not shown). This likely indicated a failed tail vein injection and this animal was excluded from further analysis. As expected from prior studies(l 1, 26), AAV-F displayed a significant increase (p=0.008) of 45-fold compared to AAV9 at biodistribution to brain (Fig. 3b). In contrast AAV-SC3 displayed a similar (non-significant) biodistribution to brain compared to AAV9 (Fig. 3b). Means for vector genomes in liver were not significantly different between any of the groups (Fig. 3b).
[0218] Next, we analyzed the levels of tdT mRNA in one neurofibroma per mouse to assess transgene expression mediated by each capsid. RNA was isolated, treated withAtorney Docket No. 29539-0872WO1 / MGH 2025-338
[0219] DNase I to remove residual AAV genomes, and RT-ddPCR performed to quantify cDNA levels compared to a reference cDNA for PPIA. Interestingly with AAV-SC3, we found a 2.1 -fold increase (p=0.111) and 6.5-fold (p=0.008) increase in tdT cDNA levels over AAV9 and AAV-F, respectively (Fig. 3c). There was no significant difference of tdT cDNA levels between AAV9 and AAV-F.
[0220] To confirm expression of tdT in the neurofibroma, we immunostained sciatic nerve cryosections with an antibody against tdT and fluorescence was measured using confocal microscopy. No specific tdT immunostaining was detected in the no vector (control) mouse neurofibroma as expected (Fig. 3d). For both AAV9 and AAV-SC3 i.v. injected mice, we detected scattered transduction of cells with distinct SC cell morphology (Fig. 3d). We also detected transduction of cells with AAV-F, but the labeling was qualitatively less frequent than AAV9 and AAV-SC3, which corroborated the RT-ddPCR data (Fig. 3d). To confirm that AAV9 and AAV-SC3 were mediating transgene expression in SCs within the neurofibroma, tissue sections were immunostained for both SoxlO as well as tdT. We detected transduced, tdT immunostained cells with Sox 10-positive nuclei for both capsids, indicating transduced SCs (Fig. 3e).
[0221] Example 4. AAV-SC3 and AAV9 transduce normal nerve in mice after systemic injection
[0222] To test if AAV-SC3 can transduce naive nerve, we injected adult male C57BL / 6 mice with 1012vg (~4xl013vg / kg) of either AAV-SC3-P0-tdT or AAV9-PO-tdT. Seven weeks post-injection, tissues were harvested, and DNA extracted from liver and sciatic nerves (Fig. 7a). AAV-SC3 had slight, 1.4-fold, higher AAV genomes in sciatic nerve compared to AAV9, although this did not reach statistical significance (Fig. 7b). AAV genomes in liver were much higher for both groups than in sciatic nerves, 120-fold higher for AAV-SC3 and 331-fold higher for AAV9, respectively (Fig. 7b). Interestingly, there was a small, 1.9-fold, yet statistically significant decrease in AAV genomes in the liver with AAV-CAP.NF compared to AAV9. To assess whether the biodistribution of AAV-SC3 was more selective for sciatic nerve vs. AAV9 we calculated the sciatic nerve / liver AAV genome ratio for each animal. We observed a significant, 3.2-fold increase in selectivity of AAV-SC3 compared to AAV9 for sciatic nerve (Fig. 7c). Next, we measured the transduction of sciatic nerve using RT-ddPCR of tdT cDNA. There was a slight, non-significant,Atorney Docket No. 29539-0872WO1 / MGH 2025-338
[0223] 1.5-fold increase in tdT cDNA levels for AAV-SC3 compared to AAV9 (Fig. 7d). In liver, the amount of tdT cDNA levels were much higher, tracking with the AAV genome levels and there was a small, non-significant, 1.09-fold increase with AAV-SC3 compared to AAV9 (Fig. 7e). To assess the cellular localization of transduction, we performed confocal microscopy on immunostained sections of liver and sciatic nerve of representative animals from both vector groups and the control group (no vector). In liver, intense tdT immunofluorescence was observed in cells with hepatocyte morphology for both capsids (Fig. 7f). In sciatic nerve we stained for both tdT and SoxlO to assess transduction of SCs. For both capsids, there were only a few detectable tdT+ SoxlO -positive SCs within each examined section (Fig. 7g). Overall, this shows that while the biodistribution of AAV genomes has been significantly shifted for AAV-SC3 vs AAV9, the transgene expression has not.
[0224] Example 5. Identification of an AAV capsid variant displaying a putative laminin binding peptide with enhanced biodistribution to sciatic nerve after systemic injection.
[0225] While direct transduction of neurofibroma with AAV could be potentially useful for control of established tumors, their heterogeneous cellular composition and relatively fast cell turnover makes this a difficult challenge. Identifying capsids which could mediate gene delivery to SCs of peripheral nerves could also be useful for prophylactic treatment before neurofibroma initiation (or for other diseases that affect SCs). Since in our selection we isolated capsids from both neurofibromas and naive nerve (Fig. 2b), we selected four candidates, AAV-SC1-4 (Table 2) for further testing for naive nerve biodistribution.
[0226] Table 2. Candidates for further screening for biodistribution to sciatic nerve. Variant AA sequence % of total In vivo characteristics
[0227] reads
[0228] AAV-SC1 STTLYSP (SEQ 4% Found in mouse 1 tumor ID NO:1)
[0229] AAV-SC2 LPTPQRL (SEQ 18% A top clone in naive nerve
[0230] ID NO:2)
[0231] AAV-SC3 RPDHLPP (SEQ 3-4% Similar levels in both ID N0:3) neurofibromas
[0232] AAV-SC4 GATPSTQ (SEQ 9-11% A top clone in nerves with
[0233]
[0234] ID NO:4) and without neurofibromasAtorney Docket No. 29539-0872WO1 / MGH 2025-338
[0235] We attempted to include the most frequent variant, HPFVSLA, but vector yield for this capsid was too low for in vivo use (data not shown). Each of the four capsids were cloned into conventional rep / cap plasmids and vectors packaged an AAV expression cassette with unique barcodes for each capsid. For benchmarking purposes, we also included an AAV9 capsid also packaging a unique barcoded expression cassette. All five capsids were pooled in an equal ratio and a total of 7xlO10vg / mouse (1.4xlO10vg / capsid / mouse) were injected into n=3 adult male C57B1 / 6 mice. Two weeks later, we harvested sciatic nerves, liver, brain, and heart and isolated AAV genomes (Fig. 4a). For each tissue, the barcode inserts were amplified using PCR and NGS performed to determine the profile of each capsid. Of all the capsids, only AAV-SC4 showed an average of ~5-fold (and up to 7-fold) significant increase in sciatic nerve (Fig. 4b, c). Interestingly AAV-SC4 appears to be more selective to sciatic nerve over other tissues such as brain, heart, and liver which were not significantly increased over AAV9 (Fig. 4c). A database search revealed that the STQ peptide, contained in the GATPSTQ 7-mer, is a known laminin binding peptide(27). Laminins are glycoproteins of the extracellular matrix and critical for SC function(28).
[0236] To assess whether AAV-SC4’s increased biodistribution resulted in enhanced transduction of SCs, we compared a direct, dose-matched comparison to AAV9, both packaging the AAV-PO-tdT expression cassette. For each capsid, six C57B1 / 6 mice (3 males, 3 females) were injected intravenously with 1012vector genomes / mouse.
[0237] Seven weeks post injection, mice were euthanized and sciatic nerves harvested (Fig.
[0238] 5a). One nerve was utilized for isolation of AAV genomes and tdTomato qPCR. We observed a significant (p=0.0027), 6.3 -fold increase in AAV genomes in sciatic nerve with AAV-SC4 compared to AAV9 (Fig 5b). When mice were grouped based on vector type and sex, we noticed that AAV9 in female mice trended towards higher biodistribution than AAV9 in male mice, while AAV-SC4 biodistribution was more consistent between sexes (Figure 5c). However, this did not achieve statistical significance. We measured tdT mRNA levels using RT-ddPCR. Unexpectedly, the average tdT cDNA was higher by 1.73-fold for AAV9 compared to AAV-SC4, however there was a large variability between mice in the AAV9 group (Fig. 5d). To confirm the tdTomato cDNA expression data, we assessed transduction of SCs in sciatic nerve by immunostaining for tdTomato and SOXIO. For AAV9, similar toAtorney Docket No. 29539-0872WO1 / MGH 2025-338
[0239] prior experiments, we observed sporadic tdTomato positive cells within the nerve, with even fewer transduced cells observed for AAV-SC4 (data not shown), which aligned with the RT-ddPCR data. We wondered if AAV-SC4 might transduce other cell types in the sciatic nerve, with the P0 promoter preventing efficient tdTomato mRNA transcription in those other cells. To evaluate this, we packaged a self-complementary (sc) AAV genome which contained a strong chicken beta actin (CBA) promoter driving GFP inside AAV-SC4 (Fig 6a). Adult C57B1 / 6 mice were injected systemically with IxlO11vg (~4xl012vg / kg) of AAV-SC4-CAG-GFP and three weeks post injection sciatic nerves and livers were harvested for immunofluorescence analysis of GFP expression. We assessed transduction of liver which is generally highly transduced by AAV vectors. Robust transduction of liver was detected for the three injected mice (Fig. 6b). This confirmed that AAV-SC4 was competent at transduction of cells in vivo. Next, we assessed transduction of sciatic nerves in the three injected mice by immunostaining for GFP as well as SoxlO to mark SCs. We observed GFP positive immunostaining throughout the nerves in each mouse, in contrast to the control nerve from mice not injected with vector (Fig. 6c). While some of the GFP immunoreactivity appeared to be inside axons (no DAPI colocalization), we observed strong colocalization of GFP with SOXIO, which indicates AAV-SC4 can transduce SCs after systemic delivery in mice (Fig. 6c, d).
[0240] Example 6. Laminin binding ability of AAV-SC4
[0241] To test whether the putative laminin binding motif “STQ” in the AAV-SC4 peptide could bind to laminin, we developed a protein dot blot. First, we had the 7mer peptide of AAV-SC4, GATPSTQ synthesized with a covalently bound biotin tag. Similarly, we had the laminin binding peptide, STQNASLLSLTV, synthesized and biotinylated for positive control. Finally, we had a scrambled, biotinylated version of the SC4 peptide, QSGATTP, synthesized as a negative control. Nitrocellulose membranes were spotted with different concentrations of recombinant human laminin 1, human laminin 2, and mouse laminin 1 from 0, 100, 200, and 600 nanograms. Membranes were blocked, then incubated with one of the three biotinylated peptides, followed by streptavidin-HRP and chemiluminescence detection. Interestingly we detected strong binding for human laminins 1 and 2 with the SC4 peptide (Fig. 8a) and some binding with the positive control peptide (Fig. 8b). No binding was detected with the negative control, scrambled peptide (Fig. 8c). Interestingly for both SC4 andAtorney Docket No. 29539-0872WO1 / MGH 2025-338
[0242] the positive control peptide, no detectable binding to murine laminin 1 was detected which may have been due to the specific epitope not being in an accessible confirmation for binding to the STQ motif. In any case, binding of SC4 to human laminin provides additional support for translational potential of the capsid for targeting laminin in peripheral nerve in humans.
[0243] REFERENCES
[0244] 1. Mendell JR, Al-Zaidy SA, Rodino-Klapac LR, Goodspeed K, Gray S J, Kay CN, et al. Current Clinical Applications of In Vivo Gene Therapy with AAVs. Mol Ther. 2021;29(2):464-88.
[0245] 2. Keeler AM, Flotte TR. Recombinant Adeno-Associated Virus Gene Therapy in Light of Luxturna (and Zolgensma and Glybera): Where Are We, and How Did We Get Here? AnnuRev Virol. 2019;6(l):601-21.
[0246] 3. Ozelo MC, Mahlangu J, Pasi KJ, Giermasz A, Leavitt AD, Laffan M, et al. Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A. N Engl J Med.
[0247] 2022;386(ll):1013-25.
[0248] 4. Pipe SW, Leebeek FWG, Recht M, Key NS, Castaman G, Miesbach W, et al. Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B. N Engl J Med. 2023;388(8):706-18.
[0249] 5. Tai CH, Lee NC, Chien YH, Byrne BJ, Muramatsu SI, Tseng SH, et al. Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency. Mol Ther. 2022;30(2):509-18.
[0250] 6. Mendell JR, Sahenk Z, Lehman K, Nease C, Lowes LP, Miller NF, et al. Assessment of Systemic Delivery of rAAVrh74.MHCK7. micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial. JAMA Neurol. 2020;77(9): 1122-31.
[0251] 7. Kagiava A, Richter J, Tryfonos C, Leal-Julia M, Sargiannidou I, Christodoulou C, et al. Efficacy of AAV serotypes to target Schwann cells after intrathecal and intravenous delivery. Sci Rep. 2021;l 1(1):23358.
[0252] 8. Kagiava A, Karaiskos C, Richter J, Tryfonos C, Jennings MJ, Heslegrave AJ, et al. AAV9-mediated Schwann cell-targeted gene therapy rescues a model of demyelinating neuropathy. Gene Ther. 2021;28(10-l l):659-75.Atorney Docket No. 29539-0872WO1 / MGH 2025-338
[0253] 9. Tanguy Y, Biferi MG, Besse A, Astord S, Cohen-Tannoudji M, Marais T, et al. Systemic AAVrhlO provides higher transgene expression than AAV9 in the brain and the spinal cord of neonatal mice. Front Mol Neurosci. 2015;8:36.
[0254] 10. Homs J, Ariza L, Pages G, Udina E, Navarro X, Chillon M, et al.
[0255] Schwann cell targeting via intrasciatic injection of AAV8 as gene therapy strategy for peripheral nerve regeneration. Gene Ther. 2011;18(6):622-30.
[0256] 11. Hanlon KS, Meltzer JC, Buzhdygan T, Cheng MJ, Sena-Esteves M, Bennett RE, et al. Selection of an Efficient AAV Vector for Robust CNS Transgene Expression. Mol Ther Methods Clin Dev. 2019;15:320-32.
[0257] 12. Ortonne N, Carroll SL, Rodriguez FJ, Miller DC, Nazarian RM, Blakeley JO, et al. Assessing interobserver variability and accuracy in the histological diagnosis and classification of cutaneous neurofibromass. Neurooncol Adv.
[0258] 2020;2(Suppl l):il 17-i23.
[0259] 13. Zhu Y, Ghosh P, Chamay P, Burns DK, Parada LF. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science.
[0260] 2002;296(5569):920-2.
[0261] 14. Woolfenden S, Zhu H, Charest A. A Cre / LoxP conditional luciferase reporter transgenic mouse for bioluminescence monitoring of tumorigenesis. Genesis.
[0262] 2009;47(10):659-66.
[0263] 15. Prabhakar S, Taherian M, Gianni D, Conlon TJ, Fulci G, Brockmann J, et al. Regression of schwannomas induced by adeno-associated virus-mediated delivery of caspase-1. Hum Gene Ther. 2013;24(2): 152-62.
[0264] 16. Ivanchenko MV, Hanlon KS, Devine MK, Tenneson K, Emond F, Lafond JF, et al. Preclinical testing of AAV9-PHP.B for transgene expression in the non-human primate cochlea. Hear Res. 2020;394: 107930.
[0265] 17. Hanlon KS, Cheng M, Ferrer RM, Ryu JR, Lee B, De La Cruz D, et al. In vivo selection in non-human primates identifies AAV capsids for on-target CSF delivery to spinal cord. Mol Ther. 2024.
[0266] 18. Morrison BM, Tsingalia A, Vidensky S, Lee Y, Jin L, Farah MH, et al. Deficiency in monocarboxylate transporter 1 (MCT1) in mice delays regeneration of peripheral nerves following sciatic nerve crush. Exp Neurol. 2015;263:325-38.Atorney Docket No. 29539-0872WO1 / MGH 2025-338
[0267] 19. Wu J, Williams JP, Rizvi TA, Kordich JJ, Witte D, Meijer D, et al. Plexiform and dermal neurofibromas and pigmentation are caused by Nfl loss in desert hedgehog-expressing cells. Cancer Cell. 2008; 13(2): 105-16.
[0268] 20. Ribeiro S, Napoli I, White IJ, Parrinello S, Flanagan AM, Suter U, et al. Injury signals cooperate with Nfl loss to relieve the tumor-suppressive environment of adult peripheral nerve. Cell Rep. 2013;5(l): 126-36.
[0269] 21. Rizvi TA, Akunuru S, de Courten-Myers G, Switzer RC, 3rd, Nordlund ML, Ratner N. Region-specific astrogliosis in brains of mice heterozygous for mutations in the neurofibromatosis type 1 (Nfl) tumor suppressor. Brain Res. 1999;816(1):111-23.
[0270] 22. Hinderer C, Katz N, Buza EL, Dyer C, Goode T, Bell P, et al. Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno- Associated Virus Vector Expressing Human SMN. Hum Gene Ther. 2018;29(3):285-98.
[0271] 23. Huang Q, Chen AT, Chan KY, Sorensen H, Barry AJ, Azari B, et al. Targeting AAV vectors to the central nervous system by engineering capsid-receptor interactions that enable crossing of the blood-brain barrier. PLoS Biol.
[0272] 2023;21(7):e3002112.
[0273] 24. Kawabata H, Konno A, Matsuzaki Y, Sato Y, Kawachi M, Aoki R, et al. Improving cell-specific recombination using AAV vectors in the murine CNS by capsid and expression cassette optimization. Mol Ther Methods Clin Dev.
[0274] 2024;32(l): 101185.
[0275] 25. Beharry A, Gong Y, Kim JC, Hanlon KS, Nammour J, Hieber K, et al. The AAV9 Variant Capsid AAV-F Mediates Widespread Transgene Expression in Nonhuman Primate Spinal Cord After Intrathecal Administration. Hum Gene Ther.
[0276] 2022;33(l-2):61-75.
[0277] 26. Huang Q, Chen AT, Chan KY, Sorensen H, Barry AJ, Azari B, et al. Targeting AAV vectors to the CNS via <em>de novo< / em> engineered capsidreceptor interactions. bioRxiv. 2022:2022.10.31.514553.
[0278] 27. Akalu A, Roth JM, Caunt M, Policarpio D, Liebes L, Brooks PC. Inhibition of angiogenesis and tumor metastasis by targeting a matrix immobilized cryptic extracellular matrix epitope in laminin. Cancer Res. 2007;67(9):4353-63.Atorney Docket No. 29539-0872WO1 / MGH 2025-338
[0279] 28. Jiang M, Chen M, Liu N. Interactions between Schwann cell and extracellular matrix in peripheral nerve regeneration. Front Neurol. 2024; 15: 1372168.
[0280] 29. Dodd RD, Mito JK, Eward WC, Chitalia R, Sachdeva M, Ma Y, et al. NF1 deletion generates multiple subtypes of soft-tissue sarcoma that respond to MEK inhibition. Mol Cancer Ther. 2013; 12(9): 1906-17.
[0281] 30. Stemmer-Rachamimov AO, Louis DN, Nielsen GP, Antonescu CR, Borowsky AD, Bronson RT, et al. Comparative pathology of nerve sheath tumors in mouse models and humans. Cancer Res. 2004;64(10):3718-24.
[0282] 31. Kershner LJ, Choi K, Wu J, Zhang X, Perrino M, Salomonis N, et al. Multiple Nfl Schwann cell populations reprogram the plexiform neurofibroma tumor microenvironment. JCI Insight. 2022;7(18).
[0283] 32. Bohlen MO, McCown TJ, Powell SK, El-Nahal HG, Daw T, Basso MA, et al. Adeno-Associated Virus Capsid-Promoter Interactions in the Brain Translate from Rat to the Nonhuman Primate. Hum Gene Ther. 2020;31(21-22):1155-68.
[0284] 33. Powell SK, Samulski RJ, McCown TJ. AAV Capsid-Promoter Interactions Determine CNS Cell-Selective Gene Expression In Vivo. Mol Ther. 2020;28(5): 1373-80.
[0285] 34. Gonzalez- Sandoval A, Pekrun K, Tsuji S, Zhang F, Hung KL, Chang HY, et al. The AAV capsid can influence the epigenetic marking of rAAV delivered episomal genomes in a species dependent manner. Nat Commun. 2023;14(l):2448.
[0286] 35. Okada Y, Hosoi N, Matsuzaki Y, Fukai Y, Hiraga A, Nakai J, et al. Development of microglia-targeting adeno-associated viral vectors as tools to study microglial behavior in vivo. Commun Biol. 2022;5(l):1224.
[0287] 36. McKee KK, Yang DH, Patel R, Chen ZL, Strickland S, Takagi J, et al. Schwann cell myelination requires integration of laminin activities. J Cell Sci.
[0288] 2012;125(Pt 19):4609-19.
[0289] 37. Skoumal M, Seidlits S, Shin S, Shea L. Localized lentivirus delivery via peptide interactions. Biotechnol Bioeng. 2016; 113(9):2033-40.
[0290] 38. Chan KY, Jang MJ, Yoo BB, Greenbaum A, Ravi N, Wu WL, et al. Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. NatNeurosci. 2017;20(8): 1172-9.Atorney Docket No. 29539-0872WO1 / MGH 2025-338
[0291] 39. Drouyer M, Chu TH, Labit E, Haase F, Navarro RG, Nazareth D, et al. Novel AAV variants with improved tropism for human Schwann cells. Mol Ther Methods Clin Dev. 2024;32(2): 101234.
[0292] 40. Zincarelli C, Soltys S, Rengo G, Rabinowitz JE. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther. 2008; 16(6): 1073-80.
[0293] 41. Romo CG, Piotrowski AF, Campian JL, Diarte J, Rodriguez FJ, Bale TA, et al. Clinical, Histological and Molecular Features of Gliomas in Adults with Neurofibromatosis Type 1. Neuro Oncol. 2023.
[0294] 42. Wilson JM, Flotte TR. Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy. Hum Gene Ther. 2020;31(13-14):695-6.
[0295] 43. Hordeaux J, Lamontagne RJ, Song C, Buchlis G, Dyer C, Buza EL, et al. High-dose systemic adeno-associated virus vector administration causes liver and sinusoidal endothelial cell injury. Mol Ther. 2024;32(4):952-68.
[0296] 44. Xie J, Xie Q, Zhang H, Ameres SL, Hung JH, Su Q, et al. MicroRNA-regulated, systemically delivered rAAV9: a step closer to CNS -restricted transgene expression. Mol Ther. 2011 ; 19(3): 526-35.
[0297] 45. Krolak T, Chan KY, Kaplan L, Huang Q, Wu J, Zheng Q, et al. A High-Efficiency AAV for Endothelial Cell Transduction Throughout the Central Nervous System. Nat Cardiovasc Res. 2022;l(4):389-400.
[0298] 46. Prabhakar S, Taherian M, Gianni D, et al. Regression of schwannomas induced by adeno-associated virus-mediated delivery of caspase-1. Hum Gene Ther.
[0299] 2013;24(2): 152-162.
[0300] 47. Ahmed SG, Abdelanabi A, Doha M, Brenner GJ. Schwannoma gene therapy by adeno-associated virus delivery of the pore-forming protein Gasdermin-D. Cancer Gene Ther. 2019;26:259-267.
[0301] 48. Ahmed SG, Abdelnabi A, Maguire CA, et al. Gene therapy with apoptosis-associated speck-like protein, a newly described schwannoma tumor suppressor, inhibits schwannoma growth in vivo. Neuro Oncol. 2019;21:854-866.
[0302] 49. Prabhakar S, Beauchamp RL, Cheah PS, et al. Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2. Mol Ther Methods Clin Dev. 2022;26:169-180.Attorney Docket No. 29539-0872WO1 / MGH 2025-338
[0303] 50. Yuan R, Wang B, Wang Y, Liu P. Gene Therapy for Neurofibromatosis Type 2-Related Schwannomatosis: Recent Progress, Challenges, and Future Directions. Oncol Ther. 2024 Jun;12(2):257-276. doi: 10.1007 / s40487-024-00279-2. Epub 2024 May 17.
[0304] 51. Tamura R, Yo M, Toda M. Gene therapy and genome-editing for schwannoma in NF2-related schwannomatosis: current understanding and future directions. JNeurooncol. 2025 Jun;173(2):263-273.
[0305] 52. O'Donohue AK, Ginn SL, Burgio G, Berman Y, Dabscheck G, Schindeler A. The evolving landscape of NF gene therapy: Hurdles and opportunities. Mol Ther Nucleic Acids. 2025 Feb 3;36(1): 102475.
[0306] OTHER EMBODIMENTS
[0307] It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.
Claims
Attorney Docket No. 29539-0872WO1 / MGH 2025-338WHAT IS CLAIMED IS:
1. An AAV capsid protein comprising an amino acid sequence that comprises at least four, five, six, or all seven contiguous amino acids from the sequence GATPSTQ (SEQ ID NO:4) or RPDHLPP (SEQ ID NO:3).
2. The AAV capsid protein of claim 1, comprising the sequence RPDHLPP (SEQ ID NO:3) and GATPSTQ (SEQ ID NO:4).
3. The AAV capsid protein of claim 1, comprising the sequence GATPSTQ (SEQ ID NO:4).
4. The AAV capsid protein of claims 1 -3, wherein the AAV is AAV9.
5. The AAV capsid protein of claims 1 -4, comprising AAV9 VP 1.
6. The AAV capsid protein of claim 5, wherein the sequence is inserted in a position corresponding to amino acids 588 and 589 of SEQ ID NO:6.
7. A nucleic acid encoding the AAV capsid protein of claims 1-6.
8. An AAV comprising the capsid protein of claims 1-6, and preferably not comprising a wild type VP1, VP2, or VP3 capsid protein.
9. The AAV of claim 8, further comprising a transgene, preferably a therapeutic transgene.
10. A method of delivering a transgene to a cell, the method comprising contacting the cell with the AAV of claims 1-9.
11. The method of claim 10, wherein the cell is a schwann cell.
12. The method of claim 11, wherein the cell is in a living subject.
13. The method of claims 11, wherein the subject is a mammalian subject.
14. The method of claims 10 to 13, wherein the cell is in the peripheral nervous system (PNS) of the subject.Attorney Docket No. 29539-0872WO1 / MGH 2025-33815. The method of claim 14, wherein the subject has Neurofibromatosis type 1 (NF1) or NF2.
16. The method of claim 15, wherein the transgene is selected from the group consisting of caspase- 1 (interleukin-P-converting enzyme; ICE), the pore-forming protein Gasdermin-D, apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), functional merlin (the protein product of the NF2 gene), the NF 1 GRD domain, and CRISPR-associated protein 9 (CRISPR / Cas9) base editor with a guide RNA (gRNA) directing the base editor to correct point mutations in the NF2 gene.
17. The method of claim 14, wherein the subject has Charcot-Marie-Tooth.
18. The method of claim 17, or wherein the transgene is selected from the group consisting of peripheral myelin protein 22 (PMP22); gap junction protein beta 1 (GJB1); mitofusin 2 (MFN2); or myelin protein zero (MPZ).
19. The method of any of claims 10 to 13, wherein the cell is in the PNS of the subject, and the AAV is administered by parenteral delivery.
20. The method of claim 19, wherein the parenteral delivery is via intravenous, intraarterial, subcutaneous, intraperitoneal, or intramuscular delivery.
